These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
421 related items for PubMed ID: 23139925
1. [Claudins as prognostic factors of breast cancer]. Szász MA. Magy Onkol; 2012 Sep; 56(3):209-12. PubMed ID: 23139925 [Abstract] [Full Text] [Related]
2. Identification of a claudin-4 and E-cadherin score to predict prognosis in breast cancer. Szasz AM, Nemeth Z, Gyorffy B, Micsinai M, Krenacs T, Baranyai Z, Harsanyi L, Kiss A, Schaff Z, Tokes AM, Kulka J. Cancer Sci; 2011 Dec; 102(12):2248-54. PubMed ID: 21883696 [Abstract] [Full Text] [Related]
3. Expression of claudins-1, -4, -5, -7 and occludin in hepatocellular carcinoma and their relation with classic clinicopathological features and patients' survival. Bouchagier KA, Assimakopoulos SF, Karavias DD, Maroulis I, Tzelepi V, Kalofonos H, Karavias DD, Kardamakis D, Scopa CD, Tsamandas AC. In Vivo; 2014 Dec; 28(3):315-26. PubMed ID: 24815833 [Abstract] [Full Text] [Related]
4. Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer. Harigopal M, Berger AJ, Camp RL, Rimm DL, Kluger HM. Clin Cancer Res; 2005 Jun 01; 11(11):4083-9. PubMed ID: 15930343 [Abstract] [Full Text] [Related]
5. Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis. Jeschke U, Mylonas I, Shabani N, Kunert-Keil C, Schindlbeck C, Gerber B, Friese K. Anticancer Res; 2005 Jun 01; 25(3A):1615-22. PubMed ID: 16033070 [Abstract] [Full Text] [Related]
6. The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer. Yoshida R, Kimura N, Harada Y, Ohuchi N. Int J Oncol; 2001 Mar 01; 18(3):513-20. PubMed ID: 11179480 [Abstract] [Full Text] [Related]
8. Clinicopathological parameters and biological markers predicting non-sentinel node metastasis in sentinel node-positive breast cancer patients. Kwon Y, Ro J, Kang HS, Kim SK, Hong EK, Khang SK, Gong G, Ro JY. Oncol Rep; 2011 Apr 01; 25(4):1063-71. PubMed ID: 21258771 [Abstract] [Full Text] [Related]
10. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. Nagai MA, Gerhard R, Fregnani JH, Nonogaki S, Rierger RB, Netto MM, Soares FA. Breast Cancer Res Treat; 2011 Feb 01; 126(1):1-14. PubMed ID: 20369286 [Abstract] [Full Text] [Related]
15. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. Heimann R, Lan F, McBride R, Hellman S. Cancer Res; 2000 Jan 15; 60(2):298-304. PubMed ID: 10667580 [Abstract] [Full Text] [Related]
16. beta-catenin expression and claudin expression pattern as prognostic factors of prostatic cancer progression. Szász AM, Nyirády P, Majoros A, Szendrõi A, Szûcs M, Székely E, Tõkés AM, Romics I, Kulka J. BJU Int; 2010 Mar 15; 105(5):716-22. PubMed ID: 19818082 [Abstract] [Full Text] [Related]
18. Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas. Gerhard R, Ricardo S, Albergaria A, Gomes M, Silva AR, Logullo ÂF, Cameselle-Teijeiro JF, Paredes J, Schmitt F. Breast; 2012 Jun 15; 21(3):354-60. PubMed ID: 22464177 [Abstract] [Full Text] [Related]
19. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer. Bernardi MA, Logullo AF, Pasini FS, Nonogaki S, Blumke C, Soares FA, Brentani MM. Oncol Rep; 2012 Jan 15; 27(1):28-38. PubMed ID: 21956537 [Abstract] [Full Text] [Related]